Acute non-cardioembolic stroke
Conditions
Interventions
Dual antiplatelet group: argatoroban, aspirin 100mg (day1 200mg), cropidogrel 75mg(day1 300mg) for 7 days, after day 7 mono antiplatelet agent
Mono antiplatelet group: argatroban, aspirin 100mg (da
Sponsors
Department of Neurology Okazaki City Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. non-cardioembolic stroke within 48 hours of onset 2. small vessel disease (lacunar or BAD (branch atheromatous disease)) 3. NIHSS score below 20 points on admission 4. mRS score 0-2 before onset 5. patients written informed consent
Exclusion criteria
Exclusion criteria: 1. cardioembolic stroke 2. antithrombotic therapy (cilostazol, ticlopidine, aspirin 100mg over, clopidogrel 75mg over, anticoagulants) before onset 3. congestive heart failure 4. medical history of allergies of argatroban, aspirin, clopidogrel 5. blood pressure cannot be controlled below 180/105mmHg 6. high hemorrhagic risk 7. severe stenosis of major cerebral and cervical artery 8. patients who are not appropriate to participate in this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. NIHSS score at 7 days after admission and at day of discharge 2. modified Rankin scale score at 3 months after stroke | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. outcome at hospital discharge 2. TIA, stroke recurrence, intracranial hemorrhage, cardiovascular event within 3 months after stroke | — |
Countries
Japan
Contacts
Public ContactRyoji Nishi
Okazaki City Hospital Department of Neurology
Outcome results
None listed